Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. Nordquist · SciRah

Researcher profile · Semantic Scholar

L. Nordquist

Share profile

L. Nordquist — researcher profile on SciRah

h-index: 20
Works: 122
Citations: 4,809

Most-cited papers

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
O. Sartor, J. de Bono, K. Chi, K. Fizazi +16 more
2021New England Journal of Medicine2,077 citations Open access
Semantic Scholar
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
B. Montgomery, M. Eisenberger, M. Rettig, F. Chu +9 more
2015Clinical Cancer Research82 citations Open access
Semantic Scholar
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).
M. Morris, J. de Bono, K. Chi, K. Fizazi +15 more
202167 citations
Semantic Scholar
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Evan Y. Yu, J. Piulats, G. Gravis, P. Fong +17 more
2022European Urology66 citations Open access
Semantic Scholar
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer
C. Higano, A. Armstrong, O. Sartor, N. Vogelzang +17 more
2019Cancer66 citations Open access
Semantic Scholar
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
F. Saad, M. Hussain, Bertrand F. Tombal, K. Fizazi +14 more
2024European Urology62 citations Open access
Semantic Scholar
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
Katherine S. Virgo, E. Basch, D. Loblaw, T. Oliver +6 more
2017Journal of Clinical Oncology59 citations Open access
Semantic Scholar
Clinical Correlates of Benefit From Radium‐223 Therapy in Metastatic Castration Resistant Prostate Cancer
A. Alva, L. Nordquist, S. Daignault, S. George +9 more
2017The Prostate43 citations Open access
Semantic Scholar
eRADicAte: A Prospective Evaluation Combining Radium‐223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration‐Resistant Prostate Cancer
N. Shore, R. Tutrone, Neil F. Mariados, L. Nordquist +3 more
2017Clinical Genitourinary Cancer31 citations Open access
Semantic Scholar
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases
O. Sartor, D. Heinrich, N. Mariados, M. Méndez-Vidal +12 more
2017Annals of Oncology29 citations Open access
Semantic Scholar
177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
O. Sartor, C. la Fougère, M. Essler, S. Ezziddin +11 more
2021Journal of Nuclear Medicine26 citations Open access
Semantic Scholar
Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).
A. Sartor, Daniel Heinrich, Neil F. Mariados, M. Méndez-Vidal +11 more
2016Clinical advances in hematology & oncology : H&O22 citations Open access
Semantic Scholar
1804P APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
J. Shen, R. Pachynski, L. Nordquist, N. Adra +8 more
2023Annals of Oncology21 citations Open access
Semantic Scholar
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
K. Autio, C. Higano, L. Nordquist, L. Appleman +20 more
2023Journal for ImmunoTherapy of Cancer20 citations Open access
Semantic Scholar
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.
N. Shore, M. Morrow, T. McMullan, Kimberly A. Kraynyak +19 more
2020Molecular Therapy18 citations Open access
Semantic Scholar
Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases
O. Sartor, Daniel Heinrich, Neil Mariados, M. M. Mendez Vidal +13 more
2019The Prostate18 citations Open access
Semantic Scholar
Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy.
D. Petrylak, S. Tagawa, R. Jain, M. Bupathi +16 more
202017 citations
Semantic Scholar
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
K. Autio, E. Antonarakis, T. Mayer, D. Shevrin +23 more
2021European Urology Open Science16 citations Open access
Semantic Scholar
ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).
M. Taplin, A. Hussain, Satish Shah, N. Shore +16 more
2019Journal of Clinical Oncology16 citations
Semantic Scholar
Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.
D. Petrylak, S. Tagawa, R. Jain, M. Bupathi +15 more
2023Journal of Clinical Oncology14 citations
Semantic Scholar
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
Shilpa Gupta, L. Nordquist, M. Fleming, W. Berry +5 more
2018Clinical Cancer Research13 citations Open access
Semantic Scholar
705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)
P. Msaouel, A. Siefker-Radtke, R. Sweis, S. Mao +16 more
202012 citations Open access
Semantic Scholar
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF
R. Aggarwal, T. Beer, V. Weinberg, C. Higano +8 more
2015Clinical Genitourinary Cancer11 citations
Semantic Scholar
1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH
A. Hansen, S. Probst, R. Tutrone, M. Osman +13 more
2022Annals of Oncology10 citations Open access
Semantic Scholar
73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
Evan Y. Yu, J. Piulats, G. Gravis, P. Fong +14 more
2021Annals of Oncology10 citations Open access
Semantic Scholar
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
D. Petrylak, U. Vaishampayan, K. Patel, C. Higano +9 more
2021ESMO Open9 citations Open access
Semantic Scholar
Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)
M. Taplin, A. Hussain, Satish Shah, N. Shore +20 more
2019Clinical Trials9 citations
Semantic Scholar
The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.
J. de Bono, C. Pezaro, S. Gillessen, N. Shore +10 more
20159 citations
Semantic Scholar
Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts).
E. Small, R. Lance, C. Redfern, F. Millard +10 more
20178 citations
Semantic Scholar
612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
E. Yu, J. M. Piulats, G. Gravis, P. Fong +16 more
2021Annals of Oncology7 citations Open access
Semantic Scholar
RENAVIV: A randomized phase III, double-blind, placebo-controlled study of pazopanib with or without abexinostat in patients with locally advanced or metastatic renal cell carcinoma.
R. Aggarwal, S. Thomas, R. Hauke, L. Nordquist +1 more
2019Journal of Clinical Oncology7 citations
Semantic Scholar
Phase 1 open-label trial to evaluate the safety and immunogenicity of PAN-301-1, a novel nanoparticle therapeutic vaccine, in patients with biochemically relapsed prostate cancer.
L. Nordquist, N. Shore, J. Elist, J. Oliver +4 more
20186 citations
Semantic Scholar
A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer.
N. Shore, E. Heath, L. Nordquist, Heather H. Cheng +15 more
20176 citations
Semantic Scholar
LB-S&T-12 OPEN -LABEL PHASE II STUDY EVALUATING THE EFFICACY OF CONCURRENT ADMINISTRATION OF RADIUM RA 223 DICHLORIDE AND ABIRATERONE ACETATE IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH SYMPTOMATIC BONE METASTASES (ERADICATE)
N. Shore, R. Tutrone, L. Nordquist, Neil F. Mariados +2 more
20166 citations
Semantic Scholar
Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.
C. Kyriakopoulos, G. Chatta, A. Laccetti, N. Iannotti +12 more
2024Journal of Clinical Oncology5 citations
Semantic Scholar
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial
N. Shore, Maha Hussain, Fred Saad, K. Fizazi +9 more
2023The Oncologist5 citations Open access
Semantic Scholar
Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer.
M. Morris, A. Sartor, J. Wong, S. Max +6 more
2022Journal of Clinical Oncology5 citations
Semantic Scholar
Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26].
Evan Y. Yu, J. Piulats, G. Gravis, P. Fong +17 more
2022European Urology5 citations Open access
Semantic Scholar
Phase II study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (UC) after checkpoint inhibitor therapy (CIT).
G. Doshi, N. Vogelzang, D. Richards, Daniel Chong +7 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
Final results from a phase i clinical trial evaluating the safety, immunogenicity, and anti-tumor activity of SNS-301 in men with biochemically relapsed prostate cancer.
L. Nordquist, H. Ghanbari, J. Elist, J. Oliver +4 more
2018Annals of Oncology5 citations Open access
Semantic Scholar
1641P Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
C. Kyriakopoulos, G. Chatta, A. L. Laccetti, N. Iannotti +12 more
2024Annals of Oncology4 citations
Semantic Scholar
177 Lu-Prostate-Speci ﬁ c Membrane Antigen Ligand After 223 Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
O. Sartor, Christian la Foug, Markus Essler, S. Ezziddin +9 more
20224 citations
Semantic Scholar
Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies.
N. Agarwal, A. Azad, A. Fay, J. Carles +9 more
20184 citations
Semantic Scholar
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
Evan Y. Yu, S. Yazji, Yisrael Katz, E. Coates +8 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.
Geoff B. Johnson, Eva Lengyelova, L. Nordquist, V. Prasad +6 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.
L. Nordquist, Eva Lengyelova, F. Almaguel, B. Mancini +7 more
2024Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).
S. Tagawa, Charlene Thomas, N. Adra, Y. Zakharia +11 more
2023Journal of Clinical Oncology3 citations
Semantic Scholar
A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.
A. Bryce, D. Karp, S. Tagawa, L. Nordquist +9 more
2023Journal of Clinical Oncology3 citations
Semantic Scholar
SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.
L. Nordquist, Eva Lengyelova, Andrei Iagaru, B. Mancini +8 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract CT121: ARX517, an anti-PSMA ADC targeting mCRPC resistant or refractory to standard therapies: A phase 1 dose escalation and dose expansion study (ARX517-2011, NCT04662580)
John Paul Shen, R. Pachynski, L. Nordquist, N. Adra +10 more
2023Cancer Research2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Shore×16
Invite
N. Shore — researcher profile on SciRah
S. Tagawa×10
Invite
S. Tagawa — researcher profile on SciRah
J. de Bono×8
Invite
J. de Bono — researcher profile on SciRah
O. Sartor×7
Invite
O. Sartor — researcher profile on SciRah

×6

Invite

N. Vogelzang — researcher profile on SciRah

Invite

M. Taplin — researcher profile on SciRah

Invite

R. Tutrone — researcher profile on SciRah

Invite

A. Peer — researcher profile on SciRah

Invite

T. Beer — researcher profile on SciRah

Invite

M. Morris — researcher profile on SciRah

Invite

G. Gravis — researcher profile on SciRah

Invite

P. Fong — researcher profile on SciRah